<DOC>
	<DOC>NCT01795326</DOC>
	<brief_summary>A physician survey to document receipt of metabolic educational materials and assess behavior of physicians in following messages communicated through the educational materials</brief_summary>
	<brief_title>Physician Survey on Monitoring of Patients Treated With Quetiapine</brief_title>
	<detailed_description>Assessment of physician behavior regarding metabolic monitoring of patients treated with SEROQUEL® (quetiapine fumarate) Tablets and SEROQUEL® (quetiapine fumarate) Extended Release Tablets in selected countries in the EU</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Depressive Disorder, Major</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<criteria>Physicians targeted to receive the metabolic educational materials and either currently prescribe or have the potential to prescribe SEROQUEL® or SEROQUEL® XR. Physicians who have participated in a survey involving SEROQUEL® / SEROQUEL® XR in the past six months are not eligible to participate in this survey.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Effectiveness of risk minimization</keyword>
	<keyword>Metabolic monitoring</keyword>
	<keyword>Seroquel®</keyword>
	<keyword>Seroquel® XR/quetiapine fumarate</keyword>
</DOC>